KR20030081355A - 트립토판 잔기를 갖는 펩티드의 합성공정 - Google Patents
트립토판 잔기를 갖는 펩티드의 합성공정 Download PDFInfo
- Publication number
- KR20030081355A KR20030081355A KR10-2003-7008232A KR20037008232A KR20030081355A KR 20030081355 A KR20030081355 A KR 20030081355A KR 20037008232 A KR20037008232 A KR 20037008232A KR 20030081355 A KR20030081355 A KR 20030081355A
- Authority
- KR
- South Korea
- Prior art keywords
- boc
- trp
- peptide
- resin
- pro
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 55
- 230000008569 process Effects 0.000 title claims abstract description 48
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 44
- 230000015572 biosynthetic process Effects 0.000 title claims description 14
- 238000003786 synthesis reaction Methods 0.000 title claims description 14
- 125000006239 protecting group Chemical group 0.000 claims abstract description 17
- 238000002955 isolation Methods 0.000 claims abstract description 8
- 238000010532 solid phase synthesis reaction Methods 0.000 claims abstract description 7
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims abstract description 7
- 239000007787 solid Substances 0.000 claims abstract description 6
- 229920005989 resin Polymers 0.000 claims description 72
- 239000011347 resin Substances 0.000 claims description 72
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 54
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 38
- 239000000243 solution Substances 0.000 claims description 38
- -1 organic acid salt Chemical class 0.000 claims description 29
- 229940024606 amino acid Drugs 0.000 claims description 25
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 22
- 150000001413 amino acids Chemical class 0.000 claims description 22
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims description 16
- 229910021529 ammonia Inorganic materials 0.000 claims description 16
- 230000008878 coupling Effects 0.000 claims description 14
- 238000010168 coupling process Methods 0.000 claims description 14
- 238000005859 coupling reaction Methods 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims description 12
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 11
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 10
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 claims description 8
- NQIHMZLGCZNZBN-PXNSSMCTSA-N Trp-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)N)C(O)=O)=CNC2=C1 NQIHMZLGCZNZBN-PXNSSMCTSA-N 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 8
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical class [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 claims description 7
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 150000007524 organic acids Chemical class 0.000 claims description 7
- 150000003141 primary amines Chemical class 0.000 claims description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 150000003335 secondary amines Chemical class 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 239000012454 non-polar solvent Substances 0.000 claims description 6
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims description 6
- 150000001408 amides Chemical class 0.000 claims description 5
- 239000007822 coupling agent Substances 0.000 claims description 5
- 150000004702 methyl esters Chemical class 0.000 claims description 5
- 238000005897 peptide coupling reaction Methods 0.000 claims description 5
- 239000007790 solid phase Substances 0.000 claims description 5
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 4
- 125000003941 D-tryptophan group Chemical group [H]C1=C([H])C([H])=C2C(C([C@@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 claims description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims description 4
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 claims description 4
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 239000012047 saturated solution Substances 0.000 claims description 4
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 claims description 4
- AYMLQYFMYHISQO-QMMMGPOBSA-N (2s)-3-(1h-imidazol-3-ium-5-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CN=CN1 AYMLQYFMYHISQO-QMMMGPOBSA-N 0.000 claims description 3
- CNBUSIJNWNXLQQ-NSHDSACASA-N (2s)-3-(4-hydroxyphenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CNBUSIJNWNXLQQ-NSHDSACASA-N 0.000 claims description 3
- JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 claims description 3
- 239000004793 Polystyrene Substances 0.000 claims description 3
- 229920002223 polystyrene Polymers 0.000 claims description 3
- WXYGVKADAIJGHB-ZDUSSCGKSA-N (2s)-3-(1h-indol-2-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound C1=CC=C2NC(C[C@H](NC(=O)OC(C)(C)C)C(O)=O)=CC2=C1 WXYGVKADAIJGHB-ZDUSSCGKSA-N 0.000 claims description 2
- FHOAKXBXYSJBGX-YFKPBYRVSA-N (2s)-3-hydroxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](CO)C(O)=O FHOAKXBXYSJBGX-YFKPBYRVSA-N 0.000 claims description 2
- JLIWGTMHYWJUPM-JEDNCBNOSA-N (2s)-3-hydroxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid;hydrate Chemical compound O.CC(C)(C)OC(=O)N[C@@H](CO)C(O)=O JLIWGTMHYWJUPM-JEDNCBNOSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims description 2
- 235000019454 L-leucine Nutrition 0.000 claims description 2
- 239000004395 L-leucine Substances 0.000 claims description 2
- MDXGYYOJGPFFJL-QMMMGPOBSA-N N(alpha)-t-butoxycarbonyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)OC(C)(C)C MDXGYYOJGPFFJL-QMMMGPOBSA-N 0.000 claims description 2
- 238000007664 blowing Methods 0.000 claims description 2
- 229960003136 leucine Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000003472 neutralizing effect Effects 0.000 claims description 2
- 235000005985 organic acids Nutrition 0.000 claims description 2
- 238000010583 slow cooling Methods 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 2
- 238000010511 deprotection reaction Methods 0.000 claims 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 abstract description 4
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 abstract description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 abstract description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 54
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 51
- 239000000047 product Substances 0.000 description 19
- 235000001014 amino acid Nutrition 0.000 description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 8
- VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 5
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 5
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000010647 peptide synthesis reaction Methods 0.000 description 5
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- NFVNYBJCJGKVQK-CYBMUJFWSA-N (2r)-3-(1h-indol-3-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound C1=CC=C2C(C[C@@H](NC(=O)OC(C)(C)C)C(O)=O)=CNC2=C1 NFVNYBJCJGKVQK-CYBMUJFWSA-N 0.000 description 3
- NFVNYBJCJGKVQK-ZDUSSCGKSA-N N-[(Tert-butoxy)carbonyl]-L-tryptophan Chemical compound C1=CC=C2C(C[C@H](NC(=O)OC(C)(C)C)C(O)=O)=CNC2=C1 NFVNYBJCJGKVQK-ZDUSSCGKSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229960003121 arginine Drugs 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 229940028334 follicle stimulating hormone Drugs 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229960002885 histidine Drugs 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical compound C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000006060 molten glass Substances 0.000 description 2
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- ZQEBQGAAWMOMAI-ZETCQYMHSA-N (2s)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1C(O)=O ZQEBQGAAWMOMAI-ZETCQYMHSA-N 0.000 description 1
- CNMAQBJBWQQZFZ-LURJTMIESA-N (2s)-2-(pyridin-2-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=CC=N1 CNMAQBJBWQQZFZ-LURJTMIESA-N 0.000 description 1
- HOBACDWMUXDSHY-QMMMGPOBSA-N (2s)-2-(quinolin-2-ylamino)propanoic acid Chemical compound C1=CC=CC2=NC(N[C@@H](C)C(O)=O)=CC=C21 HOBACDWMUXDSHY-QMMMGPOBSA-N 0.000 description 1
- YKTMJIVACXMIDM-ZETCQYMHSA-N (2s)-2-[bis(2,2,2-trifluoroethyl)amino]-6-[carbamimidoyl-(diaminomethylideneamino)amino]hexanoic acid Chemical compound NC(N)=NN(C(N)=N)CCCC[C@@H](C(O)=O)N(CC(F)(F)F)CC(F)(F)F YKTMJIVACXMIDM-ZETCQYMHSA-N 0.000 description 1
- LKENCKKEVBCYAE-VIFPVBQESA-N (2s)-2-[butyl-(diaminomethylideneamino)amino]-6-(diaminomethylideneamino)hexanoic acid Chemical compound CCCCN(NC(N)=N)[C@H](C(O)=O)CCCCNC(N)=N LKENCKKEVBCYAE-VIFPVBQESA-N 0.000 description 1
- LAKPFBJORILZSA-ILDUYXDCSA-N (2s)-2-amino-3-[4-(pyrazine-2-carbonylamino)cyclohexyl]propanoic acid Chemical compound C1CC(C[C@H](N)C(O)=O)CCC1NC(=O)C1=CN=CC=N1 LAKPFBJORILZSA-ILDUYXDCSA-N 0.000 description 1
- DCLJSEPKYJSEHW-HNNXBMFYSA-N (2s)-3-[1-(4-methylphenyl)sulfonylimidazol-4-yl]-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical group C1=CC(C)=CC=C1S(=O)(=O)N1C=C(C[C@H](NC(=O)OC(C)(C)C)C(O)=O)N=C1 DCLJSEPKYJSEHW-HNNXBMFYSA-N 0.000 description 1
- HSQIYOPBCOPMSS-ZETCQYMHSA-N (2s)-5-(diaminomethylideneamino)-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CCCN=C(N)N HSQIYOPBCOPMSS-ZETCQYMHSA-N 0.000 description 1
- PYFASGMPUKCEMS-ZETCQYMHSA-N (2s)-6-[carbamimidoyl-(diaminomethylideneamino)amino]-2-(dimethylamino)hexanoic acid Chemical compound CN(C)[C@H](C(O)=O)CCCCN(C(N)=N)NC(N)=N PYFASGMPUKCEMS-ZETCQYMHSA-N 0.000 description 1
- HBAHZZVIEFRTEY-UHFFFAOYSA-N 2-heptylcyclohex-2-en-1-one Chemical compound CCCCCCCC1=CCCCC1=O HBAHZZVIEFRTEY-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical group NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
- 229920001367 Merrifield resin Polymers 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 238000006258 combinatorial reaction Methods 0.000 description 1
- 150000003946 cyclohexylamines Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- OFYAYGJCPXRNBL-LBPRGKRZSA-N naphthalen-2-yl-3-alanine Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CC=CC2=C1 OFYAYGJCPXRNBL-LBPRGKRZSA-N 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- JPZXHKDZASGCLU-LBPRGKRZSA-N β-(2-naphthyl)-alanine Chemical compound C1=CC=CC2=CC(C[C@H](N)C(O)=O)=CC=C21 JPZXHKDZASGCLU-LBPRGKRZSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
- C07K1/061—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
- C07K1/068—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups for heterocyclic side chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (18)
- 다음 구조식(I)A1-A2-A3-Ser-A5-D-Trp-Leu-A8-Pro-A10-R1(I)여기서,A1은 pGlu 또는 N-Ac-D-β-Nal이고;A2는 His, D-p-Cl-Phe, 또는 D-p-F-Phe이고;A3는 Trp 또는 D-Trp이고;A5는 Tyr, NicLys, cPzACAla, 또는 PicLys이고;A8은 Arg, hArg(Et)2, hArg(Bu), hArg(CH2CF3)2, 또는 Lys(iPr)이고;A10은 Gly, D-Ala, 또는 결손된 것이고;R1은 NH2또는 NHEt임;의 펩티드를 제조하는 공정에서 다음의 단계를 포함함을 특징으로 하는 Trp 잔기를 갖는 펩티드의 합성공정:(a) Boc-A10-레신 또는 Boc-Pro-레신을 각각 생산하기 위하여 클로로메틸화된폴리스틸렌 레신 상에, 만일 A10이 존재하면, Boc-A10의 세슘 염을, 만일 A10이 존재하지 않으면, Boc-Pro를 부착하는 단계;(b) N2H-A10-레신의 유기산염 또는 N2H-Pro-레신의 유기산염을 각각 생산하기 위하여 Boc-디블록킹 유기산의 혼합물로 N2H-A10-레신 또는 N2H-Pro-레신을 혼합함에 의해 N2H-A10-레신 또는 N2H-Pro-레신을 탈 블록킹하는 단계;(c) N2H-A10-레신 또는 N2H-Pro-레신을 각각 생산하기 위하여 염기로 N2H-A10-레신의 유기산염 또는 N2H-Pro-레신의 유기산염을 중화하는 단계;(d) Boc-α-아민 보호 아미노산으로 N2H-A10-레신 또는 N2H-Pro-레신에 커플링하는 단계로 다음을 포함함, 상기 보호된 아미노산은 C-말단에서 N-말단으로 도시된 순서로 구조식(I)에서 정의된 아미노산에 상당하는 것임,(i) Boc-블록된 결합된 산물을 생산하기 위해 N2H-A10-레신 또는 N2H-Pro-레신을 펩티드 커플링제의 존재하에 Boc-α-아민 보호 아미노산과 반응하는 단계;(ii) 결합된 산물을 생산하기 위해 Boc-블록된 결합된 산물을 Boc-디블록킹 유기산과 혼합함에 의해 Boc-블록된 결합된 산물로 부터 Boc 기를 디블록킹하는 단계;(iii) Boc-블록된 결합된 산물을 생산하기 위해 결합된 산물을 펩티드 커플링제의 존재하에 다음 Boc-α-아민 보호 아미노산과 반응하는 단계;(iv) 다음 결합된 산물을 생산하기 위해 Boc-블록된 결합된 산물을 Boc-디블록킹 유기산과 혼합함에 의해 Boc-블록된 결합된 산물로 부터 Boc 기를 디블록킹하는 단계;(v) 보호된 완전한 펩티드-레신을 생산하기 위해 구조식(I)의 펩티드의 N-말단 아미노산이 커플되고 N-말단 아미노산의 Boc 기가 탈 블록될 때까지 단계(d)(iii)와 (d)(iv)를 반복하는 단계;(e) 구조식(I)의 펩티드를 생산하기 위해 보호된 완전한 펩티드-레신을 단리하고 탈보호하는 단계, 여기서 상기 단리 및 탈보호는 다음을 포함함;(i) 알코올/비활성 극성 비극성 용매 혼합물에서 보호된 완전한 펩티드-레신의 용액 제조;(ii) 용액을 약 0℃ 내지 약 10℃로 냉각;(iii) 포화용액을 얻기 위하여 용액이 암모니아로 잘 포화될 때까지 암모니아 가스 또는 에틸아민 가스를 용액 내로 서서히 불어넣어 냉각을 유지;(iv) >95%의 유리 메틸 에스테르가 암모니아 가스가 사용될 때는 대응하는 아미드로 전환되고, 에틸아민 가스가 사용될 때는 대응하는 에틸아미드로 전환될 때까지 약 15-36시간 동안 냉각없이 포화용액을 혼합;(f) 상기 용액으로 부터 상기 펩티드를 분리하는 단계.
- 제 1항에 있어서, A10이 Gly임을 특징으로 하는 Trp 잔기를 갖는 펩티드의 합성공정.
- 제 2항에 있어서, 다음 Boc-α-아민 아미노산이 C-말단에서 N-말단으로 N-α-Boc-L-프롤린, N-α-Boc-L-아르기닌ㆍHCl, N-α-Boc-L-류이신, N-α-Boc-D-트립토판(N'-인돌-포밀), N-α-Boc-L-티로신, N-α-Boc-L-세린 수화물, N-α-Boc-트립토판(N'-인돌-포밀), N-α-Boc-L-히스티딘(토실)-시클로헥실아민 염, 및 피로글루탐산이 연속적으로 결합됨을 특징으로 하는 Trp 잔기를 갖는 펩티드의 합성공정.
- 제 3항에 있어서, Trp 측쇄의 포밀 보호기는 암모니아, 일차 아민, 이차 아민 및 알코올을 포함하는 용액으로 처리함에 의해 제거됨을 특징으로 하는 Trp 잔기를 갖는 펩티드의 합성공정.
- 제 4항에 있어서, 상기 용액이 암모니아 및 메탄올을 포함함을 특징으로 하는 Trp 잔기를 갖는 펩티드의 합성공정.
- 제 5항에 있어서, 상기 구조식(I)의 펩티드가 pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2임을 특징으로 하는 Trp 잔기를 갖는 펩티드의 합성공정.
- 제 6항에 있어서, 1-하이드록시벤조트리아졸(HOBT)이 또한 N-α-Boc-D-트립토판(N'-인돌-포밀), N-α-Boc-L-티로신, N-α-Boc-L-세린 수화물, N-α-Boc-트립토판(N'-인돌-포밀)을 커플링 시 사용됨을 특징으로 하는 Trp 잔기를 갖는 펩티드의 합성공정.
- 다음 구조식(II)A1-A2-A3-Ser-A5-A6-Leu-A8-Pro-A10-R1(II)여기서,A1은 pGlu 또는 N-Ac-D-β-Nal이고;A2는 His, D-p-Cl-Phe, 또는 D-p-F-Phe이고;A3는 Trp, D-Trp, D-β-Nal 또는 D-Pal이고;A5는 Tyr, NicLys, cPzACAla, 또는 PicLys이고;A6은 D-β-Nal, D-hArg(Et)2, D-Lys(iPr), D-hArg(Bu), D-hArg(CH2CF3)2, D-His(Bzl), D-Leu, D-Pal, D-Ser(tBu), D-Trp, D-Cit, D-Arg, D-NicLys, D-PicLys 또는 D-Qal이고;A8은 Arg, hArg(Et)2, hArg(Bu), hArg(CH2CF3)2, 또는 Lys(iPr)이고;A10은 Gly, NHNHCO 또는 D-Ala, 또는 결손된 것이고;R1은 NH2또는 NHEt임;의 펩티드의 고체상 합성 공정에서, 여기서 A3또는 A6의 적어도 하나는 Trp 또는 D-Trp이고, 상기 방법은 염에 대해 불안정한 측쇄 보호기로 트립토판 잔기를 잠정적으로 보호하는 것을 포함하고 여기서 상기 보호기는 염기와 반응에 의해 고체 지지체로 부터 구조식(II)의 펩티드의 단리과정에서 제거됨을 특징으로 하는 Trp 잔기를 갖는 펩티드의 합성공정..
- 제 8항에 있어서, 상기 Trp 또는 D-Trp 측쇄 보호기는 아실기임을 특징으로 하는 Trp 잔기를 갖는 펩티드의 합성공정.
- 제 9항에 있어서, 상기 Trp 또는 D-Trp 측쇄 보호기는 암모니아, 일차 아민, 이차 아민 및 알코올을 포함하는 용액으로 처리함에 의해 제거됨을 특징으로 하는 Trp 잔기를 갖는 펩티드의 합성공정.
- 제 8항에 있어서, 상기 측쇄 보호기는 포밀기이고 상기 염기는 암모니아를 포함하는 메탄올 용액임을 특징으로 하는 Trp 잔기를 갖는 펩티드의 합성공정.
- 제 11항에 있어서, 상기 A3이 Trp임을 특징으로 하는 Trp 잔기를 갖는 펩티드의 합성공정.
- 제 1항에 있어서, 상기 A1이 pGlu이고, A2는 His이고, A5는 Tyr이고, A6는 D-Trp이고, A8이 Arg이고, A10은 Gly이고, R1은 NH2임을 특징으로 하는 Trp 잔기를 갖는 펩티드의 합성공정.
- 다음의 보호된 아미노산: Boc-Gly, Boc-Pro, Boc-Arg.HCl, Boc-Leu, Boc-D-Trp(PG-1), Boc-Tyr, Boc-Ser, Boc-Trp(PG-1), Boc-His(PG-2)을 고상 지지체 상에 연속적으로 커플링하는 단계를 포함하는 구조식 pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2의 펩티드의 고체상 합성공정에 있어서, 여기서 PG-1은 염에 대해 불안정한 보호기이고 PG-2는 His에 대한 보호기이고, 상기 공정은 상기 지지체로 부터 상기 펩티드의 단리공정과 염을 포함하는 용액으로 상기 트립토판 잔기로 부터 상기 PG-1을 제거하는 공정을 모두 포함함을 특징으로 하는 Trp 잔기를 갖는 펩티드의 합성공정.한다.
- 제 14항에 있어서, 상기 PG-1은 아실기임을 특징으로 하는 Trp 잔기를 갖는 펩티드의 합성공정.
- 제 15항에 있어서, 상기 용액은 암모니아, 일차 아민, 또는 이차 아민을 포함함을 특징으로 하는 Trp 잔기를 갖는 펩티드의 합성공정.
- 제 16항에 있어서, 상기 PG-2는 토실기임을 특징으로 하는 Trp 잔기를 갖는 펩티드의 합성공정.
- 제 14항에 있어서, 상기 PG-1은 포밀기이고 상기 용액은 암모니아를 포함함을 특징으로 하는 Trp 잔기를 갖는 펩티드의 합성공정.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IE20001079 | 2000-12-22 | ||
IE2000/1079 | 2000-12-22 | ||
PCT/IE2001/000159 WO2002051861A2 (en) | 2000-12-22 | 2001-12-19 | Process for the synthesis of a peptide having a tryptophan residue |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20030081355A true KR20030081355A (ko) | 2003-10-17 |
KR100591832B1 KR100591832B1 (ko) | 2006-06-20 |
Family
ID=11042704
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020037008232A KR100591832B1 (ko) | 2000-12-22 | 2001-12-19 | 트립토판 잔기를 갖는 펩티드의 합성공정 |
Country Status (25)
Country | Link |
---|---|
US (1) | US7122628B2 (ko) |
EP (1) | EP1343808B1 (ko) |
JP (1) | JP4064817B2 (ko) |
KR (1) | KR100591832B1 (ko) |
CN (2) | CN1481389A (ko) |
AT (1) | ATE339442T1 (ko) |
AU (1) | AU2002222439C1 (ko) |
BR (1) | BR0116447B1 (ko) |
CA (1) | CA2432708C (ko) |
CZ (1) | CZ299141B6 (ko) |
DE (1) | DE60123115T2 (ko) |
DK (1) | DK1343808T3 (ko) |
ES (1) | ES2266104T3 (ko) |
HK (1) | HK1055749A1 (ko) |
HU (2) | HU230601B1 (ko) |
IE (1) | IES20011090A2 (ko) |
IL (2) | IL156258A0 (ko) |
MX (1) | MXPA03005678A (ko) |
NO (1) | NO325038B1 (ko) |
NZ (1) | NZ526990A (ko) |
PL (1) | PL205949B1 (ko) |
PT (1) | PT1343808E (ko) |
RU (1) | RU2276156C2 (ko) |
WO (1) | WO2002051861A2 (ko) |
ZA (1) | ZA200304809B (ko) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7091311B2 (en) | 1996-06-07 | 2006-08-15 | Smithkline Beecham Corporation | Peptides and compounds that bind to a receptor |
BR0314591A (pt) | 2002-09-18 | 2005-08-09 | Ortho Mcneil Pharm Inc | Métodos de aumento de plaquetas e produção de célula tronco hematopoiética |
LT1675606T (lt) * | 2003-08-28 | 2017-11-10 | Janssen Pharmaceuticals, Inc. | Peptidai ir junginiai, kurie jungiasi prie trombopoetino receptorių |
EP1968995A1 (en) * | 2005-12-30 | 2008-09-17 | F. Hoffmann-la Roche AG | Methods for the synthesis of arginine-containing peptides |
WO2014047822A1 (zh) * | 2012-09-27 | 2014-04-03 | 深圳翰宇药业股份有限公司 | 一种制备布舍瑞林的方法 |
US9969769B2 (en) | 2014-12-19 | 2018-05-15 | Cem Corporation | Coupling method for peptide synthesis at elevated temperatures |
US10308677B2 (en) | 2014-12-19 | 2019-06-04 | Cem Corporation | Coupling method for peptide synthesis at elevated temperatures |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4211693A (en) * | 1977-09-20 | 1980-07-08 | The Salk Institute For Biological Studies | Peptides with para-substituted phenylalanine |
US4569927A (en) * | 1984-02-23 | 1986-02-11 | The Salk Institute For Biological Studies | GnRH Antagonists IV |
IL74827A (en) | 1984-05-21 | 1989-06-30 | Salk Inst For Biological Studi | Peptides active as gnrh antagonists and pharmaceutical compositions containing them |
IT1203600B (it) | 1985-12-06 | 1989-02-15 | Phidea Srl | Metodo per preparare il (d-trp6)-lhrh |
US5175254A (en) * | 1988-09-24 | 1992-12-29 | Societe D'expansion Scientifque Expansia | Solid phase peptide synthesis using a polyacrylic support in aqueous solution |
GB8822502D0 (en) * | 1988-09-24 | 1988-10-26 | Expansia Sa | New peptide synthesis method |
JPH05331188A (ja) | 1992-05-28 | 1993-12-14 | Nippon Chemiphar Co Ltd | トリペプチド、その製造方法及びエンドセリン拮抗剤 |
-
2001
- 2001-12-19 MX MXPA03005678A patent/MXPA03005678A/es active IP Right Grant
- 2001-12-19 JP JP2002552954A patent/JP4064817B2/ja not_active Expired - Lifetime
- 2001-12-19 NZ NZ526990A patent/NZ526990A/xx not_active IP Right Cessation
- 2001-12-19 EP EP01272223A patent/EP1343808B1/en not_active Expired - Lifetime
- 2001-12-19 CA CA2432708A patent/CA2432708C/en not_active Expired - Lifetime
- 2001-12-19 HU HU1400157A patent/HU230601B1/hu unknown
- 2001-12-19 ES ES01272223T patent/ES2266104T3/es not_active Expired - Lifetime
- 2001-12-19 DK DK01272223T patent/DK1343808T3/da active
- 2001-12-19 PT PT01272223T patent/PT1343808E/pt unknown
- 2001-12-19 AU AU2002222439A patent/AU2002222439C1/en not_active Expired
- 2001-12-19 WO PCT/IE2001/000159 patent/WO2002051861A2/en active IP Right Grant
- 2001-12-19 CN CNA018210384A patent/CN1481389A/zh active Pending
- 2001-12-19 CZ CZ20031634A patent/CZ299141B6/cs not_active IP Right Cessation
- 2001-12-19 IL IL15625801A patent/IL156258A0/xx active IP Right Grant
- 2001-12-19 BR BRPI0116447-3B1A patent/BR0116447B1/pt active IP Right Grant
- 2001-12-19 CN CNA2007100047879A patent/CN101003563A/zh active Pending
- 2001-12-19 PL PL361993A patent/PL205949B1/pl unknown
- 2001-12-19 US US10/451,486 patent/US7122628B2/en not_active Expired - Lifetime
- 2001-12-19 KR KR1020037008232A patent/KR100591832B1/ko active IP Right Grant
- 2001-12-19 DE DE60123115T patent/DE60123115T2/de not_active Expired - Lifetime
- 2001-12-19 RU RU2003122779/04A patent/RU2276156C2/ru not_active IP Right Cessation
- 2001-12-19 AT AT01272223T patent/ATE339442T1/de active
- 2001-12-19 HU HU0302633A patent/HU229701B1/hu unknown
- 2001-12-20 IE IE20011090A patent/IES20011090A2/en not_active IP Right Cessation
-
2003
- 2003-06-02 IL IL156258A patent/IL156258A/en unknown
- 2003-06-20 NO NO20032852A patent/NO325038B1/no not_active IP Right Cessation
- 2003-06-20 ZA ZA200304809A patent/ZA200304809B/en unknown
- 2003-11-04 HK HK03107934A patent/HK1055749A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1248700A (en) | Gnrh agonists | |
US7148195B2 (en) | LHRH antagonists having improved solubility properties | |
CN105408344B (zh) | 肽-树脂结合物及其用途 | |
KR100591832B1 (ko) | 트립토판 잔기를 갖는 펩티드의 합성공정 | |
Ruczyński et al. | Problem of aspartimide formation in Fmoc‐based solid‐phase peptide synthesis using Dmab group to protect side chain of aspartic acid | |
US5212288A (en) | Temporary minimal protection synthesis of serine-containing polypeptides | |
CN113614100A (zh) | 用于制备地加瑞克的方法 | |
AU2002222439A1 (en) | Process for the synthesis of a peptide having a tryptophan residue | |
CN115181158A (zh) | Fmoc基团裂解方法 | |
US5432263A (en) | Process for producing peptides with side chains containing imidazolinylamino, tetrahydropyrimidinylamino, or alkylguanidinyl groups | |
JP2927978B2 (ja) | Lh−rh類似体の一時的最小保護合成法 | |
AU2005202990A1 (en) | Process for the synthesis of a peptide having a tryptophan residue | |
CA1335403C (en) | Process and intermediates for lh-rh peptides | |
RU2043362C1 (ru) | Способ твердофазного синтеза пептидов | |
IL97216A (en) | Temporary minimal protection in solid phase synthesis of LH HR analogues |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130522 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20140521 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20150519 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20160517 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20170522 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20180516 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20190515 Year of fee payment: 14 |